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INTRODUCTION 
The NDDS should ideally fulfill two prerequisites which 
are; firstly, it should deliver the drug at a rate directed by 
the needs of the body, till the period of treatment; 
Secondly, it should channel the active ingredient of the 
formulation to the site of action
1,2,3
. In the past, the 
delivery of the drugs has been altered by routes such as 
topical delivery has been widely explored.. Most of the 
drugs which are developed from contemporary drug 
delivery system are hydrophobic in nature which then 
requires delivering drugs in a modified form to enhance 
the bioavailability of the drug. Niosomes and proniosomes 
can enhance the bioavailability of encapsulated drug and 
also provide the drug release in a controlled manner for 
prolonged period of time.
4
 Niosomes are novel surfactant 
vesicles, which are microscopic lamellar structures of size 
range 10-1000 nm formed on admixture of non-ionic 
surfactant of alkyl or dialkylpolyglycerol ether class and 
cholesterol with subsequent hydration in aqueous 
media.
5,6
 The properties of non-ionic surfactant vesicles 
can be modified by incorporation of various ingredients 
into the membrane,  e.g., cholesterol imparts rigidity and 
orientational order to the niosomal bilayer resulting in 
stable and less leaky vesicles
4,6
. Charge inducing agents 
like dicetyl phosphate, diacylglycerol and stearylamine 
provide electrostatic stabilization of vesicles and thus 
show increased entrapment efficiency of vesicles.
4
 
Proniosomes are also known as amphiphilic vesicles allow 
the encapsulation of hydrophilic drug in the core cavity 
and hydrophobic drugs in non-polar region within the 
bilayer
8
. The vesicles act as a depot and release the drug 
in controlled manner
10
. The therapeutic performance of 
drug molecules can be improved by delayed clearance 
from transmission, protecting the drug from biological 
environment thus providing targeted drug delivery. They 
provide enhanced drug concentration at the site of action 
after oral, parenteral and topical administration, thus 
minimize the side-effects. They release the drug by 
diffusion controlled mechanism. 
NIOSOME: - By reaction of a non ionic surfactant, 
cholesterol and a charge inducing agent with subsequent 
hydration in aqueous media and formed microscopic 
lamellar structures called niosomes. 
8-9
 it has property to 
entrap solutes in a manner analogous to liposomes and 
improves the stability of the entrapped drugs. These are 
polymeric biodegradable, biocompatible and non-
immunogenic preparation in nature. 
10-11
 
 
ABSTRACT 
Niosome are non-ionic surfactant vesicles obtained on hydration of synthetic nonionic surfactants, with or without 
incorporation of cholesterol or their lipids. They are vesicular systems similar to liposomes that can be used as carriers of 
amphiphilic and lipophilic drugs. Noisome are promising vehicle for drug delivery and being non-ionic; and Niosomes are 
biodegradable, biocompatible nonimmunogenic and exhibit flexibility in their structural characterization. Niosomes can entrap 
both hydrophilic and lipophilic drugs and can prolong the circulation of the entrapped drug in body. Proniosomes are dry 
formulation of water soluble carrier particles that are coated with surfactant. They are rehydrated to form niosomal dispersion 
immediately before use on agitation in hot aqueous media within minutes. Proniosomes and niosomes are physically stable 
during the storage and transport. Drug encapsulated in the vesicular structure of proniosomes prolong the existence of drug in 
the systematic circulation and enhances the penetration into target tissue and reduce toxicity. From a technical point of view, 
niosomes and proniosomes are promising drug carriers as they possess greater chemical stability and lack of many 
disadvantages associated with liposomes, such as high- cost and variable purity problems of phospholipids. The present review 
emphasizes on overall methods of preparation characterization and applicability of niosomes and proniosomes in targeted drug 
delivery. 
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Khindri et al                                        Journal of Drug Delivery & Therapeutics. 2015; 5(1):28-33 29 
© 2011-14, JDDT. All Rights Reserved                                                  ISSN: 2250-1177                                              CODEN (USA): JDDTAO 
STRUCTURE AND TYPES OF NIOSOME  
Niosomes are microscopic lamellar structures in size and 
constitute of nonionic surfactant of the alkyl or dialkyl 
poly glycerol ether class and cholesterol with subsequent 
hydration in aqueous media. Structurally, niosomes are 
similar to liposomes, in that they are also made up of a 
bilayer. However, the bilayer of niosomes is made up of 
non-ionic surface active agents rather than phospholipids 
of liposomes. The niosomes are classified as multi 
lamellar vesicles, large unilamellar vesicles and small 
unilamellar vesicles niosomes. The various types of 
niosomes are described below:  
1. Multi lamellar Vesicles (MLV):- It consist a number of 
bilayer surrounding the aqueous lipid compartment 
separately. The approximate size of these vesicles is 0.5- 
10 μm diameter. These vesicles are highly suited as drug 
carrier for lipophilic compounds.  
2. Large Unilamellar Vesicles (LUV):- Niosomes of this 
type have a high aqueous/lipid compartment ratio, so that 
larger volumes of bio-active materials can be entrapped 
with a very economical use of membrane lipids.  
3. Small Unilamellar Vesicles (SUV):- These small 
unilamellar vesicles are mostly prepared from 
multilamellar vesicles by sonication method, French press 
extrusion method or, homogenization method. The 
approximate sizes of small unilamellar vesicles are 0.025-
0.05 μcm diameter. They are thermodynamically unstable 
and are susceptible to aggregation and fusion. Their 
entrapped volume is small and percentage entrapment of 
aqueous solute is correspondingly low. 
12-14
 
ADVANTAGES OF NIOSOME 
1. The vesicle suspension is water–based vehicle. This 
offers high patient compliance in comparison with oily 
dosage forms and possesses an infrastructure consisting of 
hydrophilic, amphiphilic and lipophilic moieties together.  
2. The characteristics of the vesicle formulation are 
variable and controllable. The vesicles may act as a depot, 
releasing the drug in a controlled manner.  
3. They are osmotically active and stable, as well as they 
increase the stability of entrapped drug and improve oral 
bioavailability of poorly absorbed drugs, therapeutic 
performance of the drug molecules. 
15-16
 
COMPOSITIONS OF NIOSOMES:-  
The two major ingredients or components are used for the 
preparation of niosomes:  
1. Cholesterol: - It provides rigidity and proper shape, 
conformation to the niosomes preparations. 
2. The characteristics of the vesicle formulation are 
variable and controllable. The vesicles    may act as a 
depot, releasing the drug in a controlled manner.  
3. They are osmotically active and stable, as well as they 
increase the stability of entrapped drug and improve oral 
bioavailability of poorly absorbed drugs, therapeutic 
performance of the drug molecules. 
15-16
 
The non ionic surfactants possess a hydrophilic head and a 
hydrophobic tail. 
17-20
 
METHOD OF PREPARATION  
Some important methods that are used to formulate 
niosomes are as follows:  
1) Ether injection method: - In this method the niosomes 
are prepared by a slowly mixing of cholesterol and 
surfactant in ether into the preheated aqueous solution in 
particular ratio. The drugs conserved at 60° C by the 
specified gauze needle and the unilameller vesicles of the 
surfactants including drug formed due to the vaporization 
of ether and The size of niosomes resulted by this method 
alter between 50-1000 μm, which mainly based on the 
method of preparation, experimental procedure and 
conditions. 
21-23
 
2) Hand shaking method: - in this method lipid 
cholesterol and surfactant allow dissolving in some 
organic solvent (like ether, chloroform, benzene etc.) 
followed by the solvent evaporation under reduced 
pressure, which help to removing the solution mixture of 
solid surfactant and cholesterols on the round bottom 
flask‟s wall. The resulting layer (solid surfactant and 
cholesterol) then rehydrates with drug loaded aqueous 
solution with continuous shaking, results to Swelling of 
amphiphiles eventually which folds and form vesicles 
which entrap the drugs. The liquid volume entrapped in 
vesicles was found to be small i.e.5-10%. 
21-22 24
.  
3) Sonication method: - In this method, the surfactant-
cholesterol solution mixture is allow to disperse in the 
aqueous phase firstly with sonication for 10 minute at 
60°C, which results to the formulation of multilameller 
vesicles (MLV), These are further ultrasonicated either by 
probe sonicator or bath sonicator, which in turn leads to 
the formation of unilameller vesicles. 
21-24
.  
4) Reverse phase evaporation method: - in a mixture of 
ether and chloroform (1:1) the solution of cholesterol and 
surfactant is prepared and the drug containing aqueous 
solution is added and allow to sonicat at temperature 45°C 
in it and The solution obtained by this further sonicated 
with addition of phosphate buffer saline (PBS) which 
results to the formation of gel. This gel formation allows 
to heat with addition of PBS on water bath at 60°C for 10 
minute to yield niosomes. 
24-25
 
5) Trans membrane pH gradient drug uptake process 
(Remote Loading): - this method principles, that the 
interior of niosome has the low pH value (acidic pH) as 
compare to the outer side and the added unionized basic 
drug acrosses the membrane but after entering into the 
niosome it gets ionized in acidic medium and is unable to 
leave the niosome and thus this method increases the 
entrapment efficiency of such drugs. The acidic pH 
towards the interior of Niosomes acts as an intravascular 
trap for the drugs. 
26
. 
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6) Micro fluidization method: - In this method two 
fluidized streams solution (one containing drug and the 
other surfactant) reacts together at ultra high velocity, in 
precisely defined micro channels within the interaction 
chamber in such a way that the energy supplied to the 
system remains in the area of niosomes formations and 
this is known as submerged jet principle. It results in 
better uniformity, smaller size and reproducibility in the 
formulation of niosomes 
27-29
.  
7) Multiple membrane extrusion method: - In this 
method, the niosome‟s size is decreased/reduced by 
passing them by membrane filter. It can be used for 
production of multi lamellar vesicles as well as large 
unilamellar vesicles and It is found as a good method for 
controlling niosomal size. 
29-30
.  
8) Ethanol injection method: - in ethanol injection 
method an alcoholic (ethanol) solution of surfactant is 
employed to inject rapidly by the help of a fine needle into 
excess of saline or other aqueous medium, then the 
vaporization of ethanol results to the formation of 
vesicles. It has been reported as one of the alternatives 
used for the preparation of small unilamellar vesicles 
(SUVs) without sonication. 
30-31
.  
PRONIOSOMES 
Proniosomes: are dry formulations which make use of 
carriers coated with non-ionic surfactants and can be 
converted into niosomes immediately before use by 
hydration. Proniosomes minimize problems of niosomes 
physical stability such as aggregation, fusion, and leaking, 
and provide additional convenience in transportation, 
distribution, storage and dosing 
48
. Proniosomes-derived 
niosomes are as good as or even better than conventional 
niosomes. Proniosomes offer a versatile vesicle drug 
delivery concept with potential for delivery of drugs via 
transdermal route. This would be possible if proniosomes 
form niosomes upon hydration with water from skin 
following topical application under occlusive conditions 
49
. Transdermal therapeutic system have generated an 
interest as they provide considerable advantage of a non-
invasive parentral route for drug therapy, avoidance of 
first pass gut and hepatic metabolism, decreased side 
effects and relative ease of drug input termination in 
problematic case. Colloidal particulate carriers such as 
liposomes or niosomes have been widely employed in 
drug delivery systems and producing them from 
proniosomes provides them a distinctive advantage. These 
carriers act as drug reservoirs and the rate of drug release 
can be controlled by modification of their composition. To 
get the desired characteristics of a particular proniosome 
formulation, it is important to select the surfactant of 
suitable Hydrophilic Lipophilic Balance (HLB) number in 
the formulation of proniosome. The studies on vesicles 
systems till date open the door for the future use of 
different carrier with biocompatibility and suitability for 
the preparation of proniosomes. 
Method of Preparation  
Three different methods were reported for the preparation 
of proniosomes as described below: 
Slurry Method  
By this method proniosomes can be prepared from a stock 
solution of surfactants and cholesterol in a suitable 
solvent. The required volume of surfactant and cholesterol 
stock solution per gram of carrier and drug are firstly 
dissolved in the solvent in 100 ml round bottom flask 
containing the carrier (maltodextrin or lecithin). 
Additional chloroform can be added to form the slurry in 
case of lower surfactant loading. Further, the flask has to 
be attached to a rotary flash evaporator to evaporate 
solvent at 50–60 rpm at a temperature of 45 ± 2°C and at a 
reduced pressure of 600 mm Hg until the mass in the flask 
becomes a dry free flowing product. The formulation 
should be stored in a tightly closed container under 
refrigeration under light 
51
. 
Coacervation Phase Separation Method  
This method is widely adopted to prepare proniosomal 
gel. Precisely weighed amounts of surfactant, lipid and 
drug are taken in a clean and dry wide mouthed glass vial 
of 5.0 ml capacity and alcohol (0.5 ml) is added to it. 
After warming, all the ingredients are mixed well with a 
glass rod, the open end of the glass bottle is covered with 
a lid to prevent the loss of solvent from itand warmed over 
water bath at 60-70°C for about 5 min until the surfactant 
mixture is dissolved completely. Then the aqueous phase 
(phosphate buffer pH 7.4) is added and warmed on a 
water bath till a clear solution is formed which is then 
converted into proniosomal gel on cooling 
52
. 
Slow Spray-Coating Method 
This method involves preparation of proniosomes by 
spraying surfactant in organic solvent onto carrier material 
and then evaporating the solvent. Since, the carrier is 
soluble in the organic solvent, the process is repeated until 
the desired surfactant loading has been achieved. The 
surfactant coating on the carrier is very thin and hydration 
of this coating allows multilamellar vesicles to form as the 
carrier dissolves. The resulting niosomes are very similar 
to those produced by conventional methods and the size 
distribution is more uniform 
53
. 
 Advantage of Proniosome
54
 
1 Avoiding problem of physical stability like aggregation, 
fusion, leaking of niosomes 
2 Avoiding hydrolysis of encapsulated drugs which 
limiting the shelf life of the dispersion.             
3 Avoid first pass metabolism 
4 Minimize side effect            
5 improve bioavilability and stability problems 
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APPLICATIONS OF NIOSOMES AND 
PRONIOSOMES 
Niosomal drug delivery is potentially applicable to many 
pharmacological agents for their action against various 
diseases. Some of their therapeutic applications are 
discussed below.  
Niosomes as Drug Carriers  
Niosomes have also been used as carriers for iobitridol, a 
diagnostic agent used for X ray imaging. Topicalniosomes 
may serve as solubilization matrix, as a local depot for 
sustained release of dermally active compounds, as 
penetration enhancers, or as rate-limiting membrane 
barrier for the modulation of systemic absorption of drugs 
32
.  
Drug Targetting  
One of the most useful aspects of niosomes is their ability 
to target drugs. Niosomes can be used to target drugs to 
the reticuloendothelial system. The reticulo-endothelial 
system (RES) preferentially takes up niosome vesicles. 
The uptake of niosomes is controlled by circulating serum 
factors called opsonins. These opsonins mark the niosome 
for clearance. Such localization of drugs is utilized to treat 
tumors in animals known to metastasize to the liver and 
spleen. This localization of drugs can also be used for 
treating parasitic infections of the liver. Niosomes can 
also be utilized for targeting drugs to organs other than the 
RES. A carrier system (such as antibodies) can be 
attached to niosomes (as immunoglobulin‟s bind readily 
to the lipid surface of the niosome) to target them to 
specific organs. 
Anti-neoplastic Treatment  
Most antineoplastic drugs cause severe side effects. 
Niosomes can alter the metabolism; prolong circulation 
and half life of the drug, thus decreasing the side effects 
of the drugs. Niosomes, decreases rate of proliferation of 
tumor and higher plasma levels accompanied by slower 
elimination 
32
.  
Delivery of Peptide Drugs  
Oral peptide drug delivery has long been faced with a 
challenge of bypassing the enzymes which would 
breakdown the peptide. Use of niosomes to successfully 
protect the peptides from gastrointestinal peptide 
breakdown is being investigated. In an invitro study 
conducted by oral delivery of a vasopressin derivative 
entrapped in niosomes showed that entrapment of the drug 
significantly increased the stability of the peptide 
33
.  
Use in Studying Immune Response  
Due to their immunological selectivity, low toxicity and 
greater stability; niosomes are being used to study the 
nature of the immune response provoked by antigens. 
Non-ionic surfactant vesicles have clearly demonstrated 
their ability to function as adjuvants following parenteral 
administration with a number of different antigens and 
peptides. 
Niosomes as Carriers for Haemoglobin  
Niosomes can be used as carriers for haemoglobin within 
the blood. The niosomal vesicle is permeable to oxygen 
and hence can act as a carrier for haemoglobin in anemic 
patients.  
Leishmaniasis  
Leishmaniasis is a disease in which a parasite of the genus 
Leishmania invades the cells of the liver and 
spleen.Niosomes can be used for targeting of drug in the 
treatment of diseases in which the infecting organism 
resides in the organ of reticuloendothelial system (RES). 
The commonly prescribed drugs are antimonials, which 
are related to arsenic, and at high concentration they 
damage the heart, liver and kidney. 
34
 It was reported that 
increased sodium stibogluconate efficacy of niosomal 
formulation and that the effect of two doses given on 
successive days was additive. 
35
 Pawar SD et al reported 
that the use of niosomes to administer higher levels of the 
drug without triggering of the side effects, and thus 
allowed greater efficacy in treatment 
36
. 
Transdermal drug delivery delivery  
The major drawback of transdermal route of delivery is 
slow penetration of drug through skin, and increase in the 
penetration rate has been achieved by transdermal 
delivery of drug incorporated in niosomes. 
37
 
Cosmetic delivery 
The first report of non-ionic surfactant vesicles came from 
the cosmetic applications devised by L‟Oreal. Niosomes 
were developed and patented by L‟Oréal in the 1970s and 
80s. The first product „Niosome‟ was introduced in 1987 
by Lancôme. The advantages of using niosomes in 
cosmetic and skin care applications include their ability to 
increase the stability of entrapped drugs, improved 
bioavailability of poorly absorbed ingredients and 
enhanced skin penetration. 
38
 
Hormone delivery 
The in-vitro permeation of estradiol from vesicular 
formulations through human stratum corneum was 
studied. The vesicles were composed of non-ionic n-alkyl 
polyoxyethylene ether surfactants (CnEOm). Two 
mechanisms are proposed to play an important role in 
vesicle–skin interactions, i.e., the penetration enhancing 
effect of surfactant molecules and the effect of the 
vesicular structures caused by their adsorption at the 
stratum corneum suspension interface 
39
. 
Neoplasia 
Doxorubicin, the anthracyclic antibiotic with broad 
spectrum anti tumor activity, shows a dose dependant 
irreversible cardio toxic effect. Niosomal delivery of this 
drug to mice bearing S- 180 tumor increased their life 
span and decreased the rate of proliferation of sarcoma. 
Niosomal entrapment increased the half-life of the drug, 
prolonged its circulation and altered its metabolism. 
Intravenous administration of methotrexate entrapped in 
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niosomes to S-180 tumor bearing mice resulted in total 
regression of tumor and also higher plasma level and 
slower elimination. 
40-42
 
Vaccine delivery 
An interesting group of vaccine carrier systems are 
formulations based on non-ionic surfactant vesicles 
(niosomes) which themselves are only weekly 
immunogenic. Niosomes are gaining wide attention as per 
oral vaccine delivery system and for topical 
immunization. Influence of the varying proportion of 
surfactant, cholesterol, and dicetyl phosphate on the 
morphology, particle size, entrapment efficiency, and in-
vitro antigen release from niosomes was investigated. The 
immune stimulating activity was investigated and it was 
observed that topical niosomes elicited a comparable 
serum antibody titer and endogenous cytokines levels as 
compared to intramuscular recombinant HBsAg and 
topical liposome‟s. 43-44.  
Other Applications  
a) Sustained Release  
Sustained release action of niosomes can be applied to 
drugs with low therapeutic index and low water solubility 
since those could be maintained in the circulation via 
niosomal encapsulation 
45
. 
b) Localized Drug Action  
Drug delivery through niosomes is one of the approaches 
to achieve localized drug action, since their size and low 
penetrability through epithelium and connective tissue 
keeps the drug localized at the site of administration 
46-47
  
CONCLUSION    
Proniosomes niosomes are very promising as drug 
carriers.Compared to liposomes of natural or synthetic 
phospholipids, niosomes have the advantage that chemical 
degradation problems, such as oxidation and hydrolysis, 
may be largely alleviated. Compared to liposome or 
niosome suspensions, proniosomes represent a significant 
improvement by eliminating physical stability problems, 
such as aggregation or fusion of vesicles and leaking of 
entrapped drugs during long-term storage. Compared to 
niosomes prepared by conventional means, proniosome-
derived niosomes are superior in their convenience of 
storage, transport and dosing. The release data indicate 
that proniosome-derived niosomes are at least as effective 
as conventional niosomes in their release characteristics, 
and may therefore offer improved bioavailability of some 
drugs with poor solubility, controlled release 
formulations, or reduced adverse effects of some drugs. 
Because proniosomes are a dry powder, further processing 
is possible. To provide convenient unit dosing, the 
proniosome powder may be processed to make beads, 
tablets, gel or capsules. one of the greatest advances 
offered by proniosomes is their ease of use. The hydration 
of proniosome powder is much easier than the long 
shaking process required to hydrate surfactants in the 
conventional dry film method and can be implementedin a 
„point-of-use‟ application. Proniosome derived niosome 
suspensions appear to be as good as or better than 
conventional noisome preparations, and may be an 
appropriate preparation to use as a hydrophobic drug 
carrier.
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